MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Acceleron Pharma Company Profile (NASDAQ:XLRN)

Consensus Ratings for Acceleron Pharma (NASDAQ:XLRN) (?)
Ratings Breakdown: 2 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $55.17 (117.11% upside)

Analysts' Ratings History for Acceleron Pharma (NASDAQ:XLRN)
Show:
DateFirmActionRatingPrice TargetActions
2/1/2016OppenheimerReiterated RatingOutperform$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/20/2016Credit SuisseInitiated CoverageOutperform$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/16/2016FBR & Co.Initiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/15/2016FBR & Co.Boost Price TargetOutperform$60.00 -> $63.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/17/2015Janney Montgomery ScottReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/7/2015OppenheimerReiterated RatingBuy$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/19/2015OppenheimerInitiated CoverageOutperform -> Outperform$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2015Leerink SwannReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/13/2015Morgan StanleyInitiated CoverageOverweight$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2015FBR & Co.Initiated CoverageHold$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015JMP SecuritiesBoost Price TargetMarket Outperform$52.00 -> $58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015Citigroup Inc.Boost Price TargetBuy$50.00 -> $52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2015FBR & Co.Reiterated RatingOutperform$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/9/2015Janney Montgomery ScottInitiated CoverageBuy$51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2014Leerink SwannInitiated CoverageOutperform$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/13/2014FBR & Co.Initiated CoverageOutperform$47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/13/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by the American Association of Individual Investors As Featured by Seeking Alpha